How Travis Rush is Reinventing Health Screening with Reperio Health
Jennifer Pierce
Contributor
Many people wait until they are sick before they visit the doctor. Travis Rush, founder and CEO of Reperio Health, wants to change how people view healthcare by emphasizing the importance of preventive measures. Reperio Health offers at-home preventive care screenings with instant results, allowing people to take charge of their well-being.
People often avoid preventive care because of the cost and inaccessibility of seeing a doctor for wellness screenings. Reperio Health, however, uses patented technology paired with a mobile app and FDA-cleared devices to bring a consumer-grade experience to annual preventive screenings. In less than 30 minutes, the screenings assess key health indicators like cholesterol, glucose levels, and blood pressure, allowing users to stay informed and on top of their health, all from the comfort of their own homes.
After completing the screenings, Reperio Health virtually connects users with a healthcare professional to review the results. Using AI, Reperio summarizes five years of health history so doctors can better understand actions needed to improve the user's well-being.
Reperio Health envisions a world where everyone can easily manage their health without waiting for costly lab results. The health kit includes everything needed to complete wellness screenings and is mailed directly to the user's home. The company hopes to offer medication delivery as part of its future expansions.
To learn more about Reperio Health and how to order your health kit, visit https://www.reperiohealth.com/.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Breyers Ice Creams Recalled After Flavor Containing Life-Threatening Allergen Was Packaged as Another Flavor
6,668 cases of Breyers Chocolate Truffle Ice Cream across the United States have been recalled by Unilever Manufacturing The affected ice cream cartons actually contain Rocky Road Ice Cream, which contains almonds, a potentially "life-threatening" allergen The U.S. Food and Drug Administration announced the recall on June 10Over 6,600 cases of Breyers Ice Cream have been recalled amid concerns that the product is mislabeled and contains a "life-threatening" allergen. The U.S. Food and Drug Administration confirmed that 6,668 cases of Breyers Chocolate Truffle Ice Cream were voluntarily recalled by Unilever Manufacturing on June 2 in a Tuesday, June 10 statement. The cause for the recall was determined to be "undeclared allergens and mislabeled product." "Rocky Road Ice was packaged with Chocolate Truffle Ice Cream labeled tub and a Rocky Road Ice Cream lid. Tub said 'may contain tree nuts' the lid said it did contain almonds," the FDA clarified about the recall. is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! The FDA declared this a Class II recall, which is defined as "a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." A representative for Breyers commented on the recall in a statement shared with PEOPLE, saying, "Unilever in the U.S. is voluntarily recalling one lot of Breyers Chocolate Truffle 1.5 quart tubs after some were found to contain Rocky Road ice cream, which includes almonds not listed on the label." The statement continued: "People with an almond allergy should not consume the product due to risk of serious or life-threatening allergic reaction. The safety and quality of our products is our top priority. For more information, consumers can visit or call 1-800-931-2826." It is unclear where exactly the cases of ice cream were distributed across the United States. The FDA reported the distribution as targeting "distribution centers and retail locations across the U.S." Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Rocky Road is a flavor of ice cream that contains almonds. Although almonds are considered tree nuts, the label for Breyers Chocolate Truffle Ice Cream only says that the product "may contain tree nuts." The Breyers recall comes a few weeks after nearly 18,000 containers of Wells Dairy ice cream and frozen yogurt were recalled due to contamination with hard plastics. Wells Enterprises, which produces Wells Dairy products, was responsible for the recall, which targeted 22 different flavors of frozen desserts. Read the original article on People
Yahoo
2 hours ago
- Yahoo
SINTX Technologies Announces Strategic Vision Focused on Expansion Across Key Sectors
New leadership and recapitalization to accelerate commercialization of proprietary silicon nitride technologies in medical and high-growth markets SALT LAKE CITY, Utah, June 12, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) ('SINTX' or the 'Company'), the only FDA-registered producer of implantable silicon nitride and a global leader in advanced ceramics, today announced a renewed corporate vision and strategic plan to accelerate commercialization and unlock the full value of its intellectual property portfolio. This follows the company's successful recapitalization in February 2025 and the restructure of its leadership team and Board of Directors. A Legacy of Innovation in Silicon Nitride In 2008 SINTX Technologies made history with the first FDA-cleared implant material that is neither metal nor plastic—but medical-grade silicon nitride. The initial clearance covered a family of interbody devices and marked a pivotal moment in spinal surgery. These implants offered a unique trifecta of benefits: antimicrobial activity, osteogenic potential, and radiographic translucency. With over 50,000 spinal implants successfully placed worldwide, SINTX has demonstrated the clinical viability and long-term advantages of this revolutionary biomaterial. Today, SINTX remains the industry leader in silicon nitride technology, with 18 issued U.S. patents and 84 pending applications. Known for its strength, biocompatibility, and infection-resistant properties, the company's proprietary ceramic platform has applications across multiple markets—including the $62 billion global orthopedic implant sector, as well as emerging fields like agribiotech and performance textiles. Renewed Vision and Mission SINTX is now taking this one step further by developing next-generation hybrid biomaterials that combine the biological performance of silicon nitride and merging the flexibility, and manufacturability of polymers like PEEK and PEKK. These new composites are being optimized for applications in spine, oral/maxillofacial (OMF), cranio-maxillofacial (CMF), and oncologic reconstruction. 'Our mission is clear: to drive sustainable growth and value creation by collaborating with market leaders who recognize the transformative potential of silicon nitride,' said Mr. Eric Olson, CEO of SINTX Technologies. 'With a strengthened balance sheet and a robust intellectual property portfolio, we are uniquely positioned to accelerate commercialization and deliver superior outcomes for patients, customers, and shareholders alike.' Strategic Initiatives and Market Expansion SINTX is actively pursuing strategic partnerships and licensing opportunities to expand the reach of its technology. The company's near-term focus includes: Joint Ventures: Collaborating with established manufacturers in orthopedics, wound care, agribiotech, and other potential sectors to integrate silicon nitride into next-generation products. IP Monetization: Unlocking value from its extensive patent portfolio through licensing agreements and technology transfer initiatives. Operational Excellence: Enhancing AI supported 3D manufacturing capabilities at its FDA cleared and ISO certified headquarters to support anticipated growth and ensure the highest quality standards. Commitment to Stakeholders As SINTX enters this new era, the Company reaffirms its commitment to transparency, disciplined execution, and long-term value creation for all stakeholders. 'We are grateful for the continued support of our shareholders and partners,' said Mr. Olson. 'Together, we will realize the full potential of silicon nitride and secure SINTX's position as a leader in advanced ceramics. For more information, please visit About SINTX Technologies, Inc. Located in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter new markets. For more information on SINTX Technologies or its materials platform, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ('PSLRA') that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy,' "future," "likely," "may," "should," "will" and similar references to future periods. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. Forward looking statements include our efforts to develop next-generation hybrid biomaterials, our expectation that will drive sustainable growth and value creation, and that we will expand the reach of our technology pursuing strategic partnerships and licensing opportunities. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, difficulty in developing and commercializing medical device technologies. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 19, 2025, and in SINTX's other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law. Business and Media Inquiries for SINTX:SINTX Technologies, Inc. 801.839.3502IR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets
Recon Supply Named Exclusive U.S. Distributor of ReShape's STIMEL-03, Lap-Band® 2.0 FLEX, and Full Product Portfolio to Reach U.S. Veterans and Active-Duty Service Members IRVINE, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing of an exclusive U.S. distribution agreement with Recon Supply. Through this new strategic partnership, Recon Supply will distribute ReShape's cutting-edge portfolio, including the STIMEL-03 neuromuscular rehabilitation device, the next-generation Lap-Band® 2.0 FLEX, and the full range of ReShape products, across the Veterans Administration (VA) and Department of Defense (DoD) healthcare systems. This collaboration will expand access to proven, life-changing treatments for more than 18 million U.S. veterans and active military personnel. 'This agreement with Recon Supply marks a pivotal step forward in ReShape's mission to expand access to innovative medical technologies that improve lives,' stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. 'Through Recon's extensive footprint across the VA and DoD healthcare systems, we look forward to bringing our FDA-cleared STIMEL-03 system, a cutting-edge neurorehabilitation platform that is transforming clinical care with real-time EMG biofeedback and personalized electrical stimulation, to veterans and military personnel recovering from stroke, injury, or surgery. Additionally, the Lap-Band® 2.0 FLEX, our next-generation, minimally invasive weight loss solution, offers a safe, adjustable option for individuals struggling with obesity. Together, these technologies reflect our commitment to delivering high-impact, clinically proven solutions to patients in need, including those who have served our country.' 'Partnering with ReShape Lifesciences aligns perfectly with our mission to deliver innovative, life-changing medical solutions to those who have served our country,' added Steve Clark, Chief Executive Officer of Recon Supply and a U.S. Marine Corps veteran. 'With established access to VA and DoD facilities through our Distribution and Pricing Agreement (DAPA), Federal Supply Schedule (FSS), and Electronic Catalog (ECAT) contracts, this agreement allows us to expand the reach of ReShape's most impactful technologies—including the STIMEL-03 rehabilitation system and the Lap-Band® 2.0 FLEX. These solutions are well-suited to the complex needs of the veteran and active-duty populations we serve. Since relaunching in 2022, Recon Supply has grown over 113% year-over-year and now distributes to 102 VA Medical Centers nationwide, with a team made up almost entirely of veterans and veteran spouses. We are proud to partner with ReShape to bring these vital solutions to the men and women who have sacrificed for our country.' About Recon SupplyRecon Supply is a trusted distributor of medical products and technologies, specializing in providing high-quality solutions to federal agencies and healthcare systems. As a Service-Disabled Veteran-Owned Small Business (SDVOSB), Recon Supply is dedicated to delivering the most innovative medical technologies while actively supporting the veteran community through hiring initiatives. With a focus on excellence and reliability, Recon Supply is committed to enhancing patient care through innovative partnerships. For more information on Recon Supply, visit About ReShape Lifesciences® ReShape Lifesciences® is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational vagal neuromodulation system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit Forward-Looking Safe Harbor Statement This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include statements about the expectations regarding the distribution arrangement of Recon Supply. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission, including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law. CONTACTSReShape Lifesciences Investor Contact:Paul F. HickeyPresident and Chief Executive Officer949-276-7223ir@ Investor Relations Contact:Rx Communications GroupMichael Miller(917)-633-6086mmiller@ Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
